Tags

Type your tag names separated by a space and hit enter

Gemfibrozil therapy in primary type II hyperlipoproteinemia: effects on lipids, lipoproteins and apolipoproteins.
Can J Cardiol. 1991 Jan-Feb; 7(1):27-33.CJ

Abstract

Gemfibrozil lowers triglycerides, low density lipoprotein (LDL) and very low density lipoprotein (VLDL) cholesterol. It also promotes a significant increase of high density lipoprotein (HDL) cholesterol. It has been established that normalization of apolipoproteins is an important protective factor against atherosclerosis. The present report examines the effectiveness of 12 months of gemfibrozil treatment on plasma lipids and apolipoproteins in types IIa (VLDL 18 +/- 2 mg cholesterol/dL) and IIb (VLDL 58 +/- 7 mg cholesterol/dL) hypercholesterolemic patients. Gemfibrozil lowered plasma triglycerides, VLDL cholesterol and apolipoprotein B (apoB), increased HDL cholesterol and apoAI levels in both groups, and induced a very substantial reduction in LDL cholesterol in type IIa patients only. Even though HDL particles were enriched in cholesterol, indicating improvement in the reverse cholesterol transport and lower risk of atherosclerosis in both groups, it is important to note that production of cholesterol-poor LDL particles and reduction in LDL cholesterol and the LDL/HDL cholesterol ratio were observed only in the normotriglyceride group (type IIa). Due to the initially elevated concentration of plasma triglycerides and VLDL in type IIb patients and the increased catabolism of VLDL to LDL during gemfibrozil therapy, this drug has a more efficient regulating effect on LDL particles in type IIa compared with type IIb hyperlipidemia.

Authors+Show Affiliations

Lipid Research Centre, Laval University Medical Centre, Ste-Foy, Quebec.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Controlled Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

2025787

Citation

Lupien, P J., et al. "Gemfibrozil Therapy in Primary Type II Hyperlipoproteinemia: Effects On Lipids, Lipoproteins and Apolipoproteins." The Canadian Journal of Cardiology, vol. 7, no. 1, 1991, pp. 27-33.
Lupien PJ, Brun D, Gagné C, et al. Gemfibrozil therapy in primary type II hyperlipoproteinemia: effects on lipids, lipoproteins and apolipoproteins. Can J Cardiol. 1991;7(1):27-33.
Lupien, P. J., Brun, D., Gagné, C., Moorjani, S., Bielman, P., & Julien, P. (1991). Gemfibrozil therapy in primary type II hyperlipoproteinemia: effects on lipids, lipoproteins and apolipoproteins. The Canadian Journal of Cardiology, 7(1), 27-33.
Lupien PJ, et al. Gemfibrozil Therapy in Primary Type II Hyperlipoproteinemia: Effects On Lipids, Lipoproteins and Apolipoproteins. Can J Cardiol. 1991 Jan-Feb;7(1):27-33. PubMed PMID: 2025787.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Gemfibrozil therapy in primary type II hyperlipoproteinemia: effects on lipids, lipoproteins and apolipoproteins. AU - Lupien,P J, AU - Brun,D, AU - Gagné,C, AU - Moorjani,S, AU - Bielman,P, AU - Julien,P, PY - 1991/1/1/pubmed PY - 1991/1/1/medline PY - 1991/1/1/entrez SP - 27 EP - 33 JF - The Canadian journal of cardiology JO - Can J Cardiol VL - 7 IS - 1 N2 - Gemfibrozil lowers triglycerides, low density lipoprotein (LDL) and very low density lipoprotein (VLDL) cholesterol. It also promotes a significant increase of high density lipoprotein (HDL) cholesterol. It has been established that normalization of apolipoproteins is an important protective factor against atherosclerosis. The present report examines the effectiveness of 12 months of gemfibrozil treatment on plasma lipids and apolipoproteins in types IIa (VLDL 18 +/- 2 mg cholesterol/dL) and IIb (VLDL 58 +/- 7 mg cholesterol/dL) hypercholesterolemic patients. Gemfibrozil lowered plasma triglycerides, VLDL cholesterol and apolipoprotein B (apoB), increased HDL cholesterol and apoAI levels in both groups, and induced a very substantial reduction in LDL cholesterol in type IIa patients only. Even though HDL particles were enriched in cholesterol, indicating improvement in the reverse cholesterol transport and lower risk of atherosclerosis in both groups, it is important to note that production of cholesterol-poor LDL particles and reduction in LDL cholesterol and the LDL/HDL cholesterol ratio were observed only in the normotriglyceride group (type IIa). Due to the initially elevated concentration of plasma triglycerides and VLDL in type IIb patients and the increased catabolism of VLDL to LDL during gemfibrozil therapy, this drug has a more efficient regulating effect on LDL particles in type IIa compared with type IIb hyperlipidemia. SN - 0828-282X UR - https://www.unboundmedicine.com/medline/citation/2025787/Gemfibrozil_therapy_in_primary_type_II_hyperlipoproteinemia:_effects_on_lipids_lipoproteins_and_apolipoproteins_ L2 - https://medlineplus.gov/hdlthegoodcholesterol.html DB - PRIME DP - Unbound Medicine ER -